NCT04236843 is a NA clinical trial of Feces in Irritable Bowel Syndrome, sponsored by Helse Fonna.

Who is sponsoring NCT04236843?

NCT04236843 is sponsored by Helse Fonna.

What drugs are being tested in NCT04236843?

Interventions in NCT04236843: Feces.

What condition does NCT04236843 study?

NCT04236843 studies Irritable Bowel Syndrome.

Is NCT04236843 still recruiting?

NCT04236843 is currently completed. Last updated 22 August 2023.

Last reviewed 2023-08-22 · How we verify

NCT04236843

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Faecal Microbiota Transplantation (FMT) in Patients With IBSmechanism(s) of Action

Completed NA Last updated 22 August 2023

What this trial tests

NA trial testing Feces in Irritable Bowel Syndrome in 186 participants. Completed in 25 March 2022.

Timeline

3 February 2020

Primary endpoint
25 March 2022

25 March 2022

Quick facts

Lead sponsor	Helse Fonna
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	186
Start date	3 February 2020
Primary completion	25 March 2022
Estimated completion	25 March 2022
Sites	1 location across Norway

Drugs / interventions tested

Feces

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

Helse Fonna — full company profile →

Who can join

Adults 18 to 75, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Two hundrad patients are randomized to either 90 g transplant, 90 g transplant twice with 1week interval into the distal small intestine via working channel of a gastroscope, or to 90 g transplant into the coecum of the colon via working channel of a colonoscope. The patients shall complete 5 questionnaires measuring symptoms, fatigue and quality of life and collect a feces sample at the baseline, and at 3, 6 and 12 months after FMT. Dysbiosis and fecal bacterial are determined by using 16S rRNA gene.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome.
El-Salhy M, Gilja OH, Hatlebakk JG. · · 2024 · cited 13× · PMID 37427566 · DOI 10.1111/nmo.14641
Factors underlying the long-term efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome.
El-Salhy M, Gilja OH, Hatlebakk JG. · · 2024 · cited 3× · PMID 38843950 · DOI 10.1016/j.micinf.2024.105372
Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females.
El-Salhy M, Gilja OH, Hatlebakk JG. · · 2024 · cited 2× · PMID 38084725 · DOI 10.1080/00365521.2023.2292479
Factors Underlying the Difference in Response to Fecal Microbiota Transplantation Between IBS Patients with Severe and Moderate Symptoms.
El-Salhy M, Hatlebakk JG. · · 2024 · cited 1× · PMID 38446309 · DOI 10.1007/s10620-024-08369-x

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other Helse Fonna trials

Trials by the same sponsor.

NCT07433491 — Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry · NA · not yet recruiting
NCT03864094 — Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine. · Phase 4 · completed
NCT04588285 — Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial · Phase 2 · unknown
NCT03861377 — Hemodynamics During Induction of General Anesthesia With Medium or Low Remifentanil Doses. · Phase 4 · completed
NCT03861364 — Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose. · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04236843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helse Fonna
Last refreshed: 22 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04236843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing